Polycystic kidney diseases (PKD) are genetic disorders characterized by progressive epithelial cyst growth leading to destruction of normally functioning renal tissue. Current therapies have focused on the cyst epithelium, and little is known about how the blood and lymphatic microvasculature modulates cystogenesis. Hypomorphic Pkd1 nl/nl mice were examined, showing that cystogenesis was associated with a disorganized pericystic network of vessels expressing platelet/endothelial cell adhesion molecule 1 and vascular endothelial growth factor receptor 3 (VEGFR3). The major ligand for VEGFR3 is VEGFC, and there were lower levels of Vegfc mRNA within the kidneys during the early stages of cystogenesis in 7-day-old Pkd1 nl/nl mice. Seven-day-old mice were treated with exogenous VEGFC for 2 weeks on the premise that this would remodel both the VEGFR3 + pericystic vascular network and larger renal lymphatics that may also affect the severity of PKD. Treatment with VEGFC enhanced VEGFR3 phosphorylation in the kidney, normalized the pattern of the pericystic network of vessels, and widened the large lymphatics in Pkd1 nl/nl mice.
Polycystic kidney diseases (PKD) are genetic disorders, usually caused by mutations affecting proteins located in primary cilia and other regions within epithelial cells. 1 Epithelial turnover, adhesion, secretion, polarity, and ciliary functions are altered in PKD and therapies have predominantly targeted these processes. 1 Much less is known about how the blood and lymphatic microvasculature surrounding kidney tubules might modulate cystogenesis. Previous studies using corrosion casting and angiography show that the vessels surrounding cysts in patients with autosomal dominant PKD are tortuous, abnormally patterned, and dilated. 2, 3 Two further studies have blocked vascular endothelial growth factor A (VEGFA) signaling, a potent pro-angiogenic factor, in a nonorthologous rat PKD model but gave contradictory results and did not examine the effect of this intervention on the microvasculature. 4, 5 We examined the blood and lymphatic microvasculature in Pkd1 nl/nl mice, which carry two hypomorphic alleles of Pkd1 6 the mouse homolog of the gene most commonly mutated in human autosomal dominant PKD. Small cysts were found in the kidneys of 1-day-old Pkd1 nl/nl mice, which became more prominent 1 week postnatally; larger cysts were observed at 3 weeks, which reached a maximum at 5 weeks of age ( Figure 1 , A-E). In wild-type mice, there was a fine reticular network of vessels around kidney tubules as , respectively; P,0.05, n=4/group) but no changes in the pattern of these vessels compared with Pkd1 wt/wt mice ( Figure 1G ). At 3 weeks of age, the pattern of CD31 + vessels was disrupted in Pkd1 nl/nl mice, with clusters of tortuous vessels around cysts ( Figure 1K ) and an increased percentage area compared with Pkd1 wt/wt animals (Supplemental Table 1 ). Despite the increased relative area occupied by the vessels, proliferating (CD31 + /Ki67 + ) endothelial cells per unit area were significantly reduced in polycystic kidneys (Supplemental Table 1 ).
Lymphatics were identified using a panel of markers including VEGF receptor 3 (VEGFR3), podoplanin, lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1) and prospero homeobox 1 (PROX1). All four proteins colocalized in large intrarenal periarterial lymphatics in both wild-type and Pkd1 nl/nl 3-week-old mice and there was no change in transverse areas with PKD (Supplemental Figure 1 , Supplemental Table 1 ). Intriguingly, we noted a second population of VEGFR3 + vessels that were negative for LYVE1, podoplanin, and PROX1. These were widely distributed in peritubular areas in wild-type mice ( Figure 1H , and L). In 1-day postnatal Pkd1 nl/nl kidneys, the VEGFR3 + area of noncystic renal tissue was increased (18.7%6 1.9 and 27.4%63.7 in Pkd1 wt/wt and Pkd1 nl/nl mice; P,0.05, n=4/group) but with no apparent changes in the pattern of the vessels compared with Pkd1 wt/wt mice ( Figure 1I ). At 3 weeks of age, the pattern of the peritubular VEGFR3 + vessels in Pkd1 nl/nl mice was disorganized ( Figure 1M ) with increased percentage area (Supplemental Table 1 ). The VEGFR3 + patterns mimicked the CD31 + distribution pattern and using double labeling we demonstrated colocalization of CD31 and VEGFR3 in the same vessels in 3-week-old wild-type and cystic mice ( Figure 1 , N-U). We postulate that these CD31 + /VEGFR3 + vessels may be a kidney-equivalent to specialized capillaries seen in endocrine glands, 7, 8 with molecular features shared with lymphatic endothelia and high permeability facilitating the reabsorption of glomerular filtrate into the circulation in healthy kidneys. 9 Subsequently, we hypothesized that targeting the microvasculature may alter PKD. We decided to focus on VEGFC, which enhances growth, survival and migration of adult lymphatic endothelia through actions on VEGFR3 with lesser effects on blood vessels via VEGFR2. [10] [11] [12] VEGFC would not only target the disorganized VEGFR3 + pericystic vessels but also the larger VEGFR3 + lymphatics, allowing us to modulate both of these vessel types. First, we examined endogenous Vegfc in Pkd1 nl/nl kidneys and found a significant decrease in Vegfc mRNA levels at day 7 (P,0.01) but no difference at day 14 or 21 compared with Pkd1 wt/wt mice ( Figure 2A ). We then provided exogenous VEGFC to 7-day-old Pkd1 wt/wt mice by administering 100 ng/g body wt of recombinant VEGFC or vehicle intraperitionally every day for 2 weeks ( Figure 2B ), a period when there is rapid growth in the size of Pkd1 nl/nl kidneys (Supplemental Figure  2) . This dose has been used for VEGFA to promote renal angiogenesis 13 and a higher dose (200 ng/g body wt) of VEGFC enhances VEGFR3 phosphorylation in vivo. 14 We found that VEGFC administration enhanced tyrosine phosphorylation of VEGFR3 in Pkd1 nl/nl kidneys versus those given PBS ( Figure 2C ). VEGFC-treated Pkd1 nl/nl mice had reduced severity of PKD as assessed by the external appearance of kidneys at autopsy ( Figure 2D ) and a significant approximate halving in kidney/body weight ratio ( Figure 2E ). Pkd1 nl/nl mice receiving VEGFC had similar body weights to those given vehicle but their absolute kidney weights were about half that of the untreated PKD littermates (1.2 g60.3 and 0.6 g60.2 in Pkd1 nl/nl given PBS and VEGFC, P,0.05). Kidneys of VEGFC-treated animals contained less prominent cysts by histology ( Figure 2 , F-I) with significantly smaller average cyst size ( Figure 2J ). VEGFC did not alter BUN and creatinine ( Figure 2 , K and L) concentrations in Pkd1 wt/wt animals; both of these parameters were strikingly increased in Pkd1 nl/nl mice given PBS, which was attenuated by VEGFC treatment. As a potential confounder, BUN can be lowered if there is liver damage but VEGFC did not affect plasma alanine aminotransferase levels ( Figure 2M ). In addition, VEGFC administration did not alter the histology of the heart, lung, liver and spleen (Figure 2 , N-U).
Therapy with VEGFC had two effects on the vasculature in Pkd1 nl/nl mice. First, it increased the numbers of VEGFR3 + /Ki67 + and CD31 + /Ki67 + proliferating endothelial cells per unit area (Supplemental Table 1 ). The pattern ( Figure 3 , A-F) and percentage area (Supplemental Table 1 ) of the CD31 + and VEGFR3 + vessels in Pkd1 nl/nl mice treated with VEGFC was more like that observed in normal kidneys. Second, VEGFC significantly increased the transverse area of the larger LYVE1 + /Prox1 + lymphatics in the kidney (Supplemental Table 1 ). However, VEGFC treatment did not significantly alter endogenous kidney mRNA levels of Veg fa, Vegfc, Vegfr2, or Vegfr3 or protein levels of VEGFC (Supplemental Figure 3) . Next, we examined if these changes in the blood and lymphatic microvasculature might correlate with the inflammatory milieu in PKD by examining CD206/ Mrc1 + alternatively activated macrophages (M2), which have been functionally implicated in PKD cyst growth. 15, 16 VEGFC significantly reduced these cells in Pkd1 nl/nl mice ( Figure 3 , G-J). Treatment also led to significantly lower renal Mrc1 levels in Pkd1 nl/nl mice ( Figure 3K ) although the reduction of another M2 marker, arginase 1 (Arg1), did not reach significance ( Figure 3L ). In contrast, none of the M1 macrophage markers tested were affected by VEGFC administration (Figure 3, M and N) . Similarly, the extent of fibrosis was unaffected, as assessed by mRNA for collagen type III, a1 (Col3a1) ( Figure 3O ).
The normalization of the pericystic network of vessels alongside reduced inflammatory macrophages suggest that the microvasculature is the prime target of VEGFC therapy, but the same results might be generated as secondary effects if the growth factor acted directly on cystic epithelia. However, VEGFC did not alter proliferation in small cysts (,0.01 mm 2 ; 2966 versus 3363 proliferating nuclei/500 cells in Pkd1 nl/nl mice treated with PBS and VEGFC) with few Ki67 + cells detected in cysts larger than this in all experimental groups. In contrast to previous reports, 3,4,17 we could not detect the VEGFC receptors VEGFR2 or VEGFR3 on the cyst epithelia by immunohistochemistry in multiple animals; contrasting markedly with clear expression in vessels on the same section ( Figure 3 , P and Q). Hence, we conclude that the prime effects of VEGFC are likely to be vascularly targeted, although we cannot fully rule out epithelial effects that could be evaluated using isolated cyst models. It will be worth re-examining the VEGFA pathway in future experiments. Previous studies were performed in Han:SPRD rats, a model which does not harbor a human PKD-relevant mutation, 18 with anti-VEGFA antibody causing worse renal function and enhanced kidney injury in one laboratory 5 whereas ribozymes to block VEGFR1 and VEGFR2 reduced cyst volume density and improved renal function in another. 4 An explanation for these findings is that simply blocking VEGFA is known to cause profound glomerular changes 19 and the effects on cystic tubules could be secondary to these. The blockade of VEGFR2 by ribozymes may favor endogenous VEGFC binding to VEGFR3
+ vessels, which our study has shown to be beneficial.
We questioned whether the positive effects of VEGFC are specific for Pkd1 mutants or have more widespread effects on cystogenesis by using mice with congenital polycystic kidneys (Cys1 cpk/cpk mice). This model is nonorthologous, but provides a rapid phenocopy of the pathology of human autosomal recessive PKD with massive collecting duct cystogenesis leading to uremic death by 3 weeks of age. 20 First, we examined 2-week-old Cys1 cpk/cpk mice and found that the CD31 + and VEGFR3 + pericystic network of vessels were also disorganized compared with Cys1 +/+ mice and that both markers colocalized (Supplemental Figure 4 ). The relative area occupied by the VEGFR3 + vessels was significantly increased in Cys1 cpk/cpk mice compared with wild-type littermates with a tendency for this to be the case for CD31 + vessels (Supplemental Table  2 ). VEGFC was again provided daily from postnatal day 7 to day 14 ( Figure  4A) ; a phase where there is rapid growth in the size of Cys1 cpk/cpk kidneys (Supplemental Figure 3) . VEGFC administration to Cys1 cpk/cpk mice led to an improvement in gross morphology ( Figure 4B ) and a significant reduction in kidney/body weight ratio compared with those treated with PBS ( Figure 4C ). Cys1 cpk/cpk receiving VEGFC had similar body weights to those given PBS but had a significantly lower kidney weight (0.6 g60.1 and 0.5 g60.1 in Cys1 cpk/cpk mice treated with PBS and VEGFC, P,0.05). VEGFC treatment, did not, however, affect BUN concentration ( Figure 4D ). Kidneys of VEGFC-treated Cys1 cpk/cpk mice had less prominent cysts (Figure 4 , E-H) with a significantly smaller average cyst size ( Figure 4I) . VEGFC increased the number of proliferating CD31 + and VEGFR3 + vessels in Cys1 cpk/cpk mice (Supplemental Table  2 ), which was associated with a reduction in the VEGFR3 + percentage area (Supplemental Table 2 ). VEGFC administration did not alter the average cross-sectional area of the larger LYVE1 + / Prox1 + lymphatics in Cys1 cpk/cpk mice. Finally, VEGFC treatment led to a modest but significantly extended survival of 1 week in Cys1 cpk/cpk mice (Figure 4J) .
In conclusion, this study shows that an abnormal pericystic network of vessels is present from the early stages of PKD and becomes more disorganized as cystogenesis progresses. We demonstrated that intervening with VEGFC enhances the phosphorylation of VEGFR3, which has been shown to lead to the proliferation, migration and rearrangement of vessels. 21 VEGFC treatment also reduces the severity of PKD, which is associated with improving the pattern of the pericystic vascular network, widening the large lymphatics and clearing inflammatory cells. The combination of these effects may have the potential to reduce edema, which is a regular feature of PKD. 22 We do not yet understand why the kidney microvasculature is abnormal in PKD. One reason is that the vessels are In each group and analysis, n=4 to n=8; data are presented as mean6SEM. *P,0.05; **P,0.01; and ***P,0.001 between groups. Bar represents 50 mm in each panel.
simply distorted as cysts grow. Alternatively, there may be intrinsic defects in the vasculature, as has been reported in the skin lymphatics in Pkd1-null and Pkd2-null mice, 22 which may explain why the effects of VEGFC are more prominent in Pkd1 nl/nl mice than Cys1 cpk/cpk . Other studies have also demonstrated a role for Pkd1 in zebrafish lymphatic vessel morphogenesis 23 Future experiments should investigate VEGFC and other vascular growth factors perhaps in combination with epithelially targeted treatments. Ideally, these studies should include a slow-onset orthologous PKD1 model such as the Pkd1 RC/RC mouse, 24 since both of the models examined here progress very quickly, which did not allow the examination of multiple stages of cyst initiation, progression and end-stage PKD. In addition, detailed studies need to be performed to determine optimal doses and timing periods for VEGFC treatment. Combining epithelial and antibodies to detect either VEGFR2 or VEGFR3 and galectin-3, a marker for cyst epithelial cells derived from the collecting duct (arrows). All data are presented as mean6SEM. *P,0.05; **P,0.01; and ***P,0.001 between groups. Bar represents 50 mm in each panel.
endothelial therapies may generate the effective treatments urgently needed for these important human diseases.
CONCISE METHODS

Animal Models
Cys1 cpk/+ (The Jackson Laboratory, Bar Harbor, ME) 20 and Pkd1 nl/wt heterozygous mice 6 were bred to generate wild-type and homozygous littermates for analysis. Cys1 cpk/+ mice were maintained on the C57BL/6J background for at least 25 generations and Pkd1 nl/wt mice were maintained on CD1 background for more than ten generations. In some experiments, wild-type and homozygous Cys1 and Pkd1 mice were injected with either 100 ng/g body wt of recombinant VEGFC (R&D Systems Europe, Abingdon, UK) or vehicle (PBS) intraperitoneally daily. The daily volume administered was 20 ml, equivalent to providing 200 ml PBS to an adult human per day, or 20 ml/day to an infant. All animal procedures were approved by the UK Home Office.
Assessment of Renal Function
Blood was collected and BUN was assessed using a commercially available assay kit, validated in mice. 25 Creatinine concentration was measured using isotope dilution electrospray mass spectrometry. Alanine aminotransferase was assessed using the Vitros 5600 clinical chemistry analyzer (Ortho Clinical Diagnostics, High Wycombe, UK). VEGFC. n=7 to n=11 in each group for A-I, n=6 for J, data are presented as mean6SEM. *P,0.05; **P,0.01; and ***P,0.001 between groups.
Histologic Analysis and Immunohistochemistry
After anesthesia, the vasculature was perfused to ensure optimal tissue preservation and maintain vessel patency with 1% paraformaldehyde in PBS from a cannula inserted through the left ventricle into the aorta. Tissues were removed, fixed further by immersion in 1% paraformaldehyde for another 1 hour, washed in PBS, dehydrated and embedded in wax; then 5-mm sections were cut. Some sections were stained with periodic acid-Schiff reagent and hematoxylin to assess the overall histology. Pictures of whole stained kidneys were taken at low magnification under a dissecting microscope and the average area of individual cysts (defined as dilated tubules .0.01 mm 2 in cross-sectional area) was determined using ImageJ particle analysis (http://rsbweb.nih.gov.ij/). 26 Immunohistochemistry was performed for CD206 (MCA2235T, AdB Serotec, Oxford, UK) with appropriate secondary antibodies conjugated to horseradish peroxidase and detected by 3,39-diaminobenzidine with the color development performed for the same duration of time for each sample. Negative controls consisted of omission of primary antibodies or substitution with preimmune serum. Photomicrographs of 20 sequential fields using a 320 objective were taken and the area of the kidney cortex containing positive immunoreactivity was analyzed as a percentage of the whole image using ImmunoRatio and ImageJ software. 27 To circumvent any effects of cyst area on the analyses, the area occupied by dilated tubules .0.01 mm 2 was subtracted from each analyzed image.
In some cases after perfusion, kidneys were prepared for cryosectioning by fixing in 1% paraformaldehyde, placing samples in 30% sucrose in PBS and embedding in Tissue-Tek optimal cutting temperature compound (Sakura Finetek, Torrance, CA). Tenmicrometer sections were permeabilized in PBS containing 0.03% Triton and then incubated in PBS-Triton containing 10% normal donkey serum (Jackson ImmunoResearch Laboratories, West Grove, PA), 0.2% BSA, and 0.1% sodium azide for 1 hour at room temperature to block nonspecific antibody binding. Sections were incubated with one or more of the following primary antibodies overnight at room temperature: CD31 (MA3105; Thermo Fisher Scientific, Waltham, MA), 28, 29 
Immunoprecipitation and Western Blotting
Five hundred micrograms of protein from kidneys of Pkd1 nl/nl mice that were given vehicle or VEGFC was isolated using RIPA buffer and incubated with Dynabead Protein G (Life Technologies, Paisley, UK) and 5 mg of VEGFR3 (R&D Systems) antibody. Bound protein was eluted, denatured and separated on SDS-8% polyacrylamide gels. After electroblotting, proteins were detected using antibodies for phosphotyrosine (05-321, EMD Millipore, Billerica, MA) or VEGFR3 (R&D Systems). For the detection of endogenous VEGFC, 50 mg of kidney protein was separated, electroblotted and probed using a VEGFC antibody (sc-1881; Santa Cruz Biotechnology); a-tubulin was used as a house-keeping protein and densitometry analysis was performed.
Real-Time PCR
RNA was extracted using the RNeasy kit (Qiagen, Crawley, UK) from whole kidneys; 500 ng of RNA was used to prepare cDNA and quantitative realtime PCR was performed for Arg1, Cd206, Col3a1, iNOS, Mcp1, Vegfa, Vegfc, Vegfr2, and Vegfr3 on a CFX96 Touch Real-Time PCR Detection System (Bio-Rad Laboratories, Ltd., Hemel Hempstead, UK) using SsoAdvanced Supermix (Bio-Rad Laboratories, Ltd.) with hypoxanthine-guanine phosphoribosyltransferase (Hprt) as a house-keeping gene. Fold-changes in gene expression were determined by the 2 2DDCT method. Primer details are available on request.
Statistical analyses
All samples were assessed blinded to treatment. Data were presented as means6SEM.
In experiments when differences between two groups were evaluated, data were analyzed by Mann-Whitney U test (IBM SPSS, Chicago, II). When three or more groups were assessed one-way ANOVA with least square difference post hoc test (IBM SPSS) was used. Survival analysis was presented using the Kaplan-Meier estimate and assessed by the log-rank test. Statistical significance was accepted at P,0.05. 
